Wockhardt Limited , a prominent player in the Indian pharmaceutical sector, has reported a turnaround in its financial performance for the second quarter of fiscal year 2026. The company posted a profit after tax of Rs. 82.00 crore for Q2FY26, compared to a loss of Rs. 109.00 crore in the previous quarter.

Financial Highlights

• Revenue from operations stood at Rs. 782.00 crore in Q2FY26, up from Rs. 738.00 crore in Q1FY26.
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a significant 58% quarter-on-quarter growth, reaching Rs. 160.00 crore in Q2FY26 compared to Rs. 101.00 crore in the previous quarter.
• The company reported a profit before tax of Rs. 91.00 crore for Q2FY26, a substantial improvement from the loss of Rs. 109.00 crore in Q1FY26.

Exit from US Generic Pharmaceutical Business

In a strategic move, Wockhardt has decided to exit the US generic pharmaceutical business. The company filed for voluntary liquidation on July 11, 2025, under Chapter 7 of the US Bankruptcy Code for its US step-down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. This decision resulted in an exceptional item charge of Rs. 97.00 crore in the financial results for the period ended September 30, 2025.

Business Performance

• The India Business reported a revenue of Rs. 172.00 crore in Q2FY26, showing a 3% growth compared to the previous year.
• UK Business revenue stood at Rs. 313.00 crore, with a 4% year-on-year growth.
• Irish Business saw significant growth, with revenue reaching Rs. 59.00 crore, a 40% increase compared to the previous year.

Novel Antibiotics Progress

Wockhardt continues to make strides in its novel antibiotics portfolio:

1. ZAYNICH®: The company submitted a New Drug Application (NDA) to the U.S. FDA in September 2025 for its novel antibacterial agent WCK 5222, ZAYNICH.

2. MIQNAF® (Nafithromycin): Approved and launched in India on May 27, 2025. The Phase 3 CABP study was published in the prestigious LANCET journal.

3. EMROK/EMROK O: Included in Clinical Infectious Disease Society's official diagnosis and treatment guidelines for 2025.

Biotech Operations

The Biotech segment showed robust growth, with overall operations for the quarter standing at Rs. 154.00 crore, recording a growth of 42% compared to Q4 FY25 and 41% versus Q1 FY26.

Intellectual Property

Wockhardt continues to strengthen its intellectual property portfolio:

• 7 patents were filed during the quarter ended September 30, 2025.
• The company was granted 5 patents during the quarter and now holds a total of 858 patents.

Wockhardt's Chairman, Dr. Habil Khorakiwala, stated, "Our focus on novel antibiotics and strategic decisions are beginning to show positive results. The exit from the US generic business allows us to concentrate on high-growth areas and innovative products."

As Wockhardt continues to navigate the challenging pharmaceutical landscape, investors and industry observers will be keenly watching its progress in novel antibiotics and the impact of its strategic decisions on future growth.

Wockhardt , a prominent Indian pharmaceutical company, has reached a significant milestone in its drug development pipeline by submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Zidebactam-Cefepime, a novel antibacterial agent aimed at treating serious Gram-negative infections.

Groundbreaking Achievement for Indian Pharmaceutical Innovation

This NDA submission marks a historic moment for the Indian pharmaceutical industry, as Zidebactam-Cefepime (WCK 5222, ZAYNICH™) is the first drug fully discovered and developed by an Indian pharmaceutical company to reach this stage with the U.S. FDA. The achievement underscores Wockhardt's commitment to addressing the global crisis of antimicrobial resistance (AMR).

Targeting Complicated Urinary Tract Infections

The NDA seeks approval for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, with or without concurrent bacteremia caused by Gram-negative bacteria, including multidrug-resistant (MDR) strains. This addresses a significant medical need, as more than 8 million cUTI cases are reported annually in the U.S. and EU combined.

Novel Mechanism of Action

Zidebactam-Cefepime represents a first-in-class β-lactam enhancer and β-lactam combination, introducing a new mechanism of action to combat difficult-to-treat infections. The drug has shown potent activity against multi-drug resistant (MDR) and extreme drug resistant (XDR) Gram-negative pathogens, including those harboring NDM carbapenemases and PBP mutations.

Robust Clinical Development

The NDA submission is supported by a comprehensive clinical development package, including:

• Nine Phase I studies conducted in the U.S. and China
• A Phase II study conducted in India
• A pivotal Phase III global clinical trial (ENHANCE 1) across 64 sites in multiple countries

Regulatory Support and Designations

Zidebactam-Cefepime has been granted Qualified Infectious Disease Product (QIDP) and Fast Track Designation by the U.S. FDA, highlighting its potential importance in addressing serious infections.

Wockhardt's Antibiotic Innovation

Dr. Habil Khorakiwala, Founder Chairman of Wockhardt Group, commented on the achievement, stating, "This milestone reflects our unwavering commitment to combat antimicrobial resistance through innovative drug discovery. Zidebactam-Cefepime has the potential to address a critical gap in the treatment of serious Gram-negative infections."

Wockhardt has been at the forefront of antibiotic innovation for over 27 years, with a pipeline of six antibiotics at various stages of clinical development and commercialization. The company's focus on combating multi-drug resistant infections has resulted in three novel antibiotics already approved for clinical use, with two more in the final stages of development.

As the global healthcare community continues to grapple with the challenge of antimicrobial resistance, Wockhardt's progress with Zidebactam-Cefepime represents a significant step forward in the development of new treatment options for serious bacterial infections.